8-K
filed May 10, 2023, 7:59 PM ET
ticker ABBV
CIK 0001551152
other material
confidence high
sentiment neutral
materiality 0.15
AbbVie shareholders elect directors, ratify auditor, approve say-on-pay; supermajority amendment fails
AbbVie Inc.
- Class II directors Alpern, Meyer, Waddell elected with 1.14B, 1.25B, and 1.21B votes respectively.
- Shareholders ratified Ernst & Young as auditor for 2023 with 1.49B votes for vs 18.7M against.
- Advisory vote on executive compensation passed with 1.14B for vs 109.3M against.
- Management proposal to eliminate supermajority voting failed (1.24B for, 1.29M against; needed supermajority).
- Stockholder proposal for simple majority voting approved with 668.5M for vs 581.3M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
AbbVie Inc. shareholders approved Election of Class II Directors at the 2023-05-05 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-05
Exact text from the filing
(1) The stockholders elected AbbVie’s Class II Directors with terms expiring in 2026, as follows: Name For Against Broker Non-Votes Robert J. Alpern 1,142,062,843 20,689,813 251,363,568 Melody B. Meyer 1,247,333,998 4,243,832 251,363,568 Frederick H. Waddell 1,208,836,612 14,319,844 251,363,568
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on lobbying at the 2023-05-05 meeting.
- Outcome
- failed
- Meeting
- 2023-05-05
Exact text from the filing
(7) The stockholders did not approve a stockholder proposal to issue an annual report on lobbying, as follows: For Against Abstain Broker Non-Votes 448,957,091 787,145,991 20,487,503 251,363,568
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
AbbVie Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2023-05-05 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-05
Exact text from the filing
(3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2023 annual meeting, as follows: For Against Abstain Broker Non-Votes 1,137,389,680 109,281,658 9,919,247 251,363,568
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
AbbVie Inc. shareholders rejected Amendment of certificate of incorporation to eliminate supermajority voting at the 2023-05-05 meeting.
- Proposal
- charter amendment
- Outcome
- failed
- Meeting
- 2023-05-05
Exact text from the filing
(4) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,241,106,832 11,289,016 4,194,737 251,363,568
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
AbbVie Inc. shareholders approved Stockholder proposal to implement simple majority voting at the 2023-05-05 meeting.
- Outcome
- passed
- Meeting
- 2023-05-05
Exact text from the filing
(5) The stockholders approved a stockholder proposal to implement simple majority voting, as follows: For Against Abstain Broker Non-Votes 668,497,335 581,300,391 6,792,859 251,363,568
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on political spending at the 2023-05-05 meeting.
- Outcome
- failed
- Meeting
- 2023-05-05
Exact text from the filing
(6) The stockholders did not approve a stockholder proposal to issue an annual report on political spending, as follows: For Against Abstain Broker Non-Votes 187,829,409 1,052,110,624 16,650,552 251,363,568
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
AbbVie Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2023 at the 2023-05-05 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-05
Exact text from the filing
(2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2023, as follows: For Against Abstain 1,486,053,290 18,676,821 3,224,042
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on patent process at the 2023-05-05 meeting.
- Outcome
- failed
- Meeting
- 2023-05-05
Exact text from the filing
(8) The stockholders did not approve a stockholder proposal to issue an annual report on patent process, as follows: For Against Abstain Broker Non-Votes 363,777,601 867,061,281 25,751,703 251,363,568
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.